2026-05-21 ワシントン大学セントルイス校
＜関連情報＞
- https://source.washu.edu/2026/05/blood-test-powered-by-ai-could-transform-diagnosis-of-dementia/
- https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71420
GPND-AI NULISA：神経変性疾患の診断および共病理プロファイリングのための15タンパク質AI分類器 GPND-AI NULISA: A 15-Protein AI classifier for diagnosis and co-pathology profiling across neurodegenerative diseases
Ying Xu, Marisa N Denkinger, Menghan Liu, Katherine Gong, Yike Chen, Daniel Western, Jigyasha Timsina, Yuchen Cheng, Yunchang Xie, Rui Mu, John Budde, Thomas G. Beach, Geidy E. Serrano, …
Alzheimer’s & Dementia Published: 28 April 2026
DOI:https://doi.org/10.1002/alz.71420
Abstract
INTRODUCTION
Accurate clinical diagnosis of neurodegenerative diseases remains challenging, particularly when individuals have mixed pathologies. We implemented the generalizable protein-based neurodegenerative disease artificial intelligence (GPND-AI) classifier using the NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) central nervous system (CNS) panel to classify Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies, and healthy controls, while disentangling mixed pathologies.
METHODS
Proteomic and clinical information from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight-ADRC) and Movement Disorder Clinic were used to train and test the GPND-AI classifier. External validation was performed in a Banner Sun Health Research Institute cohort and additional Knight-ADRC samples with neuropathologically confirmed diagnoses.
RESULTS
GPND-AI identified 15 proteins that achieve an area under the curve (AUC) of 0.955 and 92.3% accuracy across five diagnostic categories. In validation cohort, predicted co-pathologies significantly correlated with clinical characteristics.
DISCUSSION
GPND-AI identified a 15-protein panel that accurately classifies individuals across the four major neurodegenerative diseases. Validation against neuropathology-confirmed diagnoses supports the utility of proteomics-based approaches for mapping disease-specific and co-existing neurodegenerative processes.
Highlights
- A streamlined 15-protein NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) plasma panel accurately distinguished four major neurodegenerative diseases and healthy brain aging.
- In an independent external cohort, the NULISA classifier distinguished the neurodegenerative diseases as defined by neuropathology.
- Individual-level probability outputs capture early, ambiguous, and mixed pathological signatures, aligning with underlying amyloid/tau burden and cognitive decline.
